Actos

TERMINATED · PHASE2 · Type 2 Diabetes Mellitus

MBX-102 did not meet the target efficacy profile of HbA1c change.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.